Определено ли место бета-адреноблокаторов при лечении артериальной гипертонии?
Аннотация
Список литературы
1. The HDFP cooperative group. Persistence of reduction in blood pressure and mortality of participantesin the Hypertension Detection and Folloiw - up Program. JAMA 1988; 259: 2113-22.
2. Carlberg B, Samuelsson O, Lindholm L.H. Atenolol in hypertension: is it a wise chouse? Lancet 2004; 364: 1684-9.
3. Lindholm L.H, Carlberg B, Samuelsson O. Shoud b - blockers first chouse in the treatment of primary hypertension? A meta - analisys. Lancet 2005; 366: 1545-53.
4. Beevers D.G. The end of b - blockers for uncomplicated hypertension? Ibid: 1510-2.
5. Wikstrand J, Warnold I, Olsson G et al. Primary prevention with metoprolol in patients with hypertension. Mortality results grom the MAPHY study. JAMA 1988; 259 (13): 1976-82.
6. Wikstrand J. Primary prevention in patients with hypertension: Comments on the clinical implications of the MAPHY Study. Am Heart Journal July 1988; 116: 338-46.
7. Wikstrand J, Warnold I, Tuomilehto J et al. Metoprolol versus thiazide diuretics in hypertension. Morbidity results from the MAPHY study. Hypertension 1991; 17: 579-88.
8. Wilhelmsen L, Berglund G, Elmfeldt D et al. Beta-Blockers Versus Diuretics in Hypertensive Men: Main Results from the HAPPHY Trial. Journal of Hypertension 1987; 5: 561-72.
9. Maphy and the Two Arms of Happhy. JAMA 1989; 262 (23): 3272-4.
10. Овчаренко С.И., Литвинова И.В., Маколкин В.И. Применение суперселективного бета - адреноблокатора небиволола у пациентов с сердечно - сосудистой патологией в сочетании с бронхообструктивным синдромом. Рос. кардиол. журн. 2006; 2 (58): 78-82.
11. Matthys H, Giebelhaus V, Von Fallois J. Nebivolol (nebilet) a beta - blocker of the third generation - also for patients with obstructive lung diseases? Z Kardiol 2001; 90 (10): 760-5.
12. Maffei A, Vecchione C, Aretini A et al. Characterization of nitric oxide release by nebivolol and its metabolites. Am J Hypertens 2006; 19 (6): 579-86.
13. Ignarro L.J. Experimental evidences of nitric oxide - dependent vasodilatory activity of nebivolol, a third - generation beta - blocker. Blood Press Suppl 2004; 1: 2-16.
14. Dessy C, Saliez J, Ghisdal P et al. Endothelial beta-3-adrenoreceptors mediate nitric oxide - dependent vasorelaxation of coronary microvessels in response in response to the third - generation beta - blocker nebivolol. Circulation 2005; 112 (8): 1198-205.
15. Garban H.J, Buga G.M, Ignarro L.J. Estrogen - receptor mediated vascular responsiveness to nebivolol: a novel endothelium - related mechanism of therapeutic vasorelaxation. J Cardiovasc Pharmacol 2004; 43 (5): 638-44.
16. Kalinowski L, Dobrucki L.W, Szczepanska-Konkel M et al. Third - generation beta - blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. Circulation 2003; 107 (21): 2747-52.
17. Brehm B.R, Wolf S.C, Bertsch D et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49 (2): 430-9.
18. Von Fallois J, Faulhaber H.D. Nebivolol, a beta - blocker of the 3rd generation: modern therapy of arterial hypertension. Results of a multicenter observation study. Schweiz Rundsch Med Prax 2001; 90 (11): 435-41.
19. Глезер М.Г., Бойко Н.В., Абильдинова А.Ж., Соболев К.Э. Сравнительная эффективность лечения небивололом и бисопрололом больных артериальной гипертензией. Кардиоваск. тер. и проф. 2004; 3 (5): 43-50.
20. Brett S.E, Forte P, Chowienczyk P.J et al. Comparison of the effects of nebivolol and bisoprolol on systematic vascular resistance in patients with essential hypertension. Clin Drug Invest 2002; 22 (6): 355-9.
21. Бувальцев В.И., Спасская М.Б., Небиеридзе Д.В. и др. Фармакологическая модуляция синтеза NO у пациентов с артериальной гипертензией и эндотелиальной дисфункцией. Клин. мед. 2003; 81 (7): 51-5.
22. Fratta Passini A, Garbin U, Nava M.C et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23 (3): 589-96.
23. Kaplan N.M, Opie L.H. Controversies in Cardiology 2. Controversies in hypertension. Lancet 2006; 367: 168-76.
24. New BHS-NICE guidelines (June 2006). Prescription guidelines in cardiology. Editions Frison-Roche. 2006.
25. Expert consensus document on b - adrenergic receptor blockers. The task Force on Beta-Blockers of the European Society of Cardiology. Europ Heart J 2004; 25 (15): 1341-62.
Рецензия
Для цитирования:
Маколкин В.И. Определено ли место бета-адреноблокаторов при лечении артериальной гипертонии? Системные гипертензии. 2006;(2):54-57.
Послать статью по эл. почте 